ArticleSAGE open medical case reports2025
Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often resulting from factors such as obesity, hypertension, or genetic mutations. The management of secondary focal segmental glomerulosclerosis remains challenging due to the lack of standardized therapeutic guidelines. This case report describes a 21-year-old male diagnosed with biopsy-proven secondary focal segmental glomerulosclerosis, likely due to obesity-related hyperfiltration, who exhibited significant improvement in proteinuria following cyclosporine therapy. Despite initial treatment with renin-angiotensin system inhibitors and prednisone, the patient continued to have persistent proteinuria. Low-dose cyclosporine therapy was introduced, leading to a marked reduction in proteinuria without deterioration in renal function. This case highlights the potential role of cyclosporine in the management of secondary focal segmental glomerulosclerosis, particularly in cases with suspected genetic predisposition. Further research is needed to determine the long-term efficacy and safety of cyclosporine in secondary focal segmental glomerulosclerosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.